Asset
Elacestrant
Context Therapeutics Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06938711 | phase1_2 | withdrawn | 2023-06-01 | 2023-11-01 | Context Therapeutics Inc. | A Rollover Protocol of Elacestrant, in Combination With Onapristone, for Patients With ER+, PR+, HER2- Advanced or Metastatic Breast Cancer |
| NCT05618613 | phase1_2 | terminated | 2022-12-02 | 2023-06-23 | Context Therapeutics Inc. | Study of Elacestrant in Combination With Onapristone in Patients With Advanced or Metastatic Breast Cancer |
FDA applications (0)
This company has no applications containing this asset.